Agendia, Inc. a world leader in precision oncology, announced today an agreement with Imegen (Valencia, Spain), for the exclusive distribution of the MammaPrint and BluePrint breast cancer genomic tests throughout Spain and Portugal.

MammaPrint, which has extensive clinical validation, uses the proprietary, 70-gene expression profile to classify patients with breast cancer as having a "low" or "high" risk of recurrence over a period of 10 years. BluePrint provides critical subtyping information to further enhance treatment approaches. Oncologists and breast surgeons use the information provided by MammaPrint and BluePrint to guide personalized treatment strategies for each patient diagnosed with early stage breast cancer.

Mark Straley, CEO, Agendia, commented "We are very pleased to have Imegen as a partner in the distribution of MammaPrint and BluePrint because of their knowledge in the area of ??oncological genomics and experience in the Spanish market. Together, we will bring our testing expertise to the nearly 25,000 of women annually diagnosed with breast cancer on the Iberian Peninsula."

Ángela Pérez, CEO of Imegen added, "With the growing breast cancer burden globally, and increasing incidence of diagnoses in Spain and Portugal, Agendia’s product suite is a perfect complement to our OncoGenomics division. Now, we are able to help breast cancer patients, both in obtaining an appropriate diagnosis, and in the choice of a fully personalized treatment. "

About Imegen
Imegen (Institute of Genomic Medicine), the leading laboratory for genetic diagnostics in Spain, provides products and services for Precision Medicine and is a pioneer in the development of tests based on the latest DNA sequencing technologies.

About Agendia
Agendia is a privately held, leading precision oncology company that develops and markets genomic diagnostic products, which help support patients and physicians with their complex treatment decisions. Agendia’s breast cancer tests were developed using an unbiased gene selection by analyzing the complete human genome. The company’s offerings include the MammaPrint Breast Cancer Risk-of-Recurrence Test, and the BluePrint Molecular Subtyping Test, both on microarray technology, whereas the new MammaPrint BluePrint Breast Cancer Recurrence and Molecular Subtyping Kit, is on NGS technology.

The MammaPrint BluePrint next-generation sequencing-based kit is a CE-marked device currently available for use in cancer centers in select regions of the world.

In addition, Agendia has a pipeline of other genomic products in development. The company collaborates with pharmaceutical companies, leading cancer centers and academic groups to develop companion diagnostic tests in the area of oncology. For more information on Agendia or the MammaPrint and BluePrint tests, visit www.agendia.com. Follow Agendia, Inc. on Facebook, Twitter, or LinkedIn to keep up-to-date with the latest news.

About MammaPrint
MammaPrint is an in vitro diagnostic medical device, performed as a testing service in a central laboratory, using the 70-gene expression profile of breast cancer tissue samples to assess a patient’s risk for distant metastasis. The device is FDA-cleared and CE-marked, enabling use in the European Union. MammaPrint is indicated for use by physicians as a prognostic marker only, along with other clinical-pathological factors. It is not intended to determine the outcome of disease, nor to suggest or infer an individual patient’s response to therapy. MammaPrint is the only test recommended for lymph node-negative and lymph node-positive patients by both the American Society of Clinical Oncology (ASCO) and National Comprehensive Cancer Network (NCCN). The test is also recommended by many other national and international clinical practice guidelines. Please see Agendia.com for more information

About BluePrint
BluePrint is an 80-gene complementary test to MammaPrint which allows functional molecular subtyping of a breast cancer sample into three distinct subtypes: Luminal-type, HER2-type and Basal-type, each with marked differences in long-term outcome and response to neoadjuvant chemotherapy.

Register as Visitor to CPhI China 2019!

-----------------------------------------------------------------------
Editor's Note:

If you have any suggestion to the content, 

please email: Julia.Zhang@ubmsinoexpo.com.